<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320225</url>
  </required_header>
  <id_info>
    <org_study_id>ITP-vitamin D(observational)</org_study_id>
    <nct_id>NCT04320225</nct_id>
  </id_info>
  <brief_title>Connection Between Vitamin D Level and the Efficacy of Dexamethasone in Immune Thrombocytopenia</brief_title>
  <official_title>A Prospective Observational Study: Connection Between Vitamin D Level and the Efficacy of Dexamethasone in Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project was undertaking by Qilu Hospital of Shandong University in China. The objective&#xD;
      is to find out if there is a connection between vitamin D level and the efficacy of&#xD;
      dexamethasone for the treatment of adults with newly-diagnosed primary immune&#xD;
      thrombocytopenia (ITP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators anticipate to undertaking a prospective, observationalï¼Œnon-randomized&#xD;
      control trial of 60 ITP adult patients. Dexamethasone (given orally at a dose of 40 mg per&#xD;
      day for 4 days, two-cycles with an interval of 10 days) will be used in the target patients.&#xD;
      Vitamin D level will be detected before the utilization of treatment measures. Depend on the&#xD;
      vitamin D level, the patients will be divided into 2 groups(higher vitamin D level group and&#xD;
      lower vitamin D level group).Platelet count, bleeding and other symptoms were evaluated&#xD;
      before and after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained response to ITP treatments</measure>
    <time_frame>3 months after treatment started</time_frame>
    <description>Percentage of patients maintaining PLT count over 30*10^9/L without bleeding</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Lower vitamin D level group</arm_group_label>
    <description>The vitamin D level is lower than 20 nmol/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher vitamin D level group</arm_group_label>
    <description>The vitamin D level is higher than 20 nmol/L.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>HD-DXM (orally at 40 mg daily for 4d )</description>
    <arm_group_label>Higher vitamin D level group</arm_group_label>
    <arm_group_label>Lower vitamin D level group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed ITP patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Corresponding to the diagnostic criteria for immune thrombocytopenia Newly diagnosed ITP&#xD;
        patients To show a platelet count &lt;30 * 10^9/L, and with bleeding manifestations Willing&#xD;
        and able to sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within&#xD;
        3 months before the screening visit; Received second-line ITP-specific treatments (eg,&#xD;
        cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before&#xD;
        the screening visit; Received high-dose steroids or IVIG in the 3 weeks prior to the start&#xD;
        of the study; Current HIV infection; Severe medical condition (lung, hepatic or renal&#xD;
        disorder) other than chronic ITP. Unstable or uncontrolled disease or condition related to&#xD;
        or impacting cardiac function (e.g., unstable angina, congestive heart failure,&#xD;
        uncontrolled hypertension or cardiac arrhythmia) Female patients who are nursing or&#xD;
        pregnant, who may be pregnant, or who contemplate pregnancy during the study period; Have a&#xD;
        known diagnosis of other autoimmune diseases, established in the medical history and&#xD;
        laboratory findings with positive results for the determination of antinuclear antibodies,&#xD;
        anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test; Patients who are&#xD;
        deemed unsuitable for the study by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 21, 2020</study_first_submitted>
  <study_first_submitted_qc>March 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Ming Hou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

